Login
Immunogen NASDAQ: IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
| Name | Immunogen |
| Ticker | IMGN |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 7.21 |
| 52W Low/High | 2.12 / 7.66 |
| Market cap | 1.3 B |
| 1Y Total Return |
58.11%
Strong |
| 1Y Volatility |
88.96%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology.
Details
| Ticker | IMGN |
| Name | Immunogen |
| ISIN | US45253H1014 |
| CUSIP | 45253H101 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/15/21
| Close Price | 7.21 |
| 52W Low/High | 2.12 / 7.66 |
| Market cap | 1.3 B |
| 1Y Total Return |
58.11%
Strong |
| 1Y Volatility |
88.96%
High Risk |
| Beta | 2.64 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -77.7% |
| Cash from Op. / Cur. Liabilities | -1.20 |
| Diluted Earnings / Share | -0.40 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 13.8 |
| Price / Book | -29.3 |
| Price / CF | -10.5 |
| Current Ratio | 2.2 |
| Cur.Liabilities / Tot.Liabilities | 0.3 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
91
|
51
|
79
|
90
|
53
|
87
|
|
| Gross Profit |
91
|
51
|
79
|
90
|
53
|
87
|
|
| R&D |
101
|
132
|
171
|
134
|
146
|
119
|
|
| EBITDA |
-69
|
-146
|
-132
|
-107
|
-149
|
-67
|
|
| Operating Income |
-50
|
-141
|
-131
|
-78
|
-135
|
-61
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
175
|
148
|
147
|
93
|
87
|
87
|
|
| EPS exc. Extra |
-0.40
|
-1.03
|
-0.98
|
-1.31
|
-1.79
|
-0.84
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
248
|
254
|
340
|
226
|
231
|
286
|
|
| Cash, Eq & Invt ShortTerm |
188
|
204
|
303
|
195
|
196
|
248
|
|
| Total Current Assets |
219
|
226
|
323
|
207
|
207
|
262
|
|
| Total Non-Current Assets |
29
|
28
|
17
|
19
|
24
|
24
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
291
|
340
|
293
|
337
|
354
|
274
|
|
| Total Current Liabilities |
100
|
88
|
70
|
74
|
56
|
36
|
|
| Long Term Debt |
191
|
252
|
223
|
263
|
298
|
238
|
|
| Shareholder equity |
-43
|
-86
|
47
|
-111
|
-123
|
12
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-120
|
-97
|
-155
|
1
|
-141
|
-68
|
|
| Depreciation |
2
|
4
|
8
|
6
|
6
|
5
|
|
| Cash from Investing |
3
|
-4
|
-4
|
-1
|
-8
|
-9
|
|
| Capex |
3
|
4
|
4
|
1
|
8
|
9
|
|
| Cash from Financing |
101
|
2
|
267
|
-1
|
97
|
203
|
|
| Stock Issued |
101
|
2
|
267
|
0
|
1
|
9
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
97
|
0
|
|
| Free Cash Flow |
-75
|
-130
|
-143
|
-102
|
-125
|
-90
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
2.2
|
2.6
|
4.6
|
2.8
|
3.7
|
7.3
|
|
| Financial Leverage D/E |
-
|
-
|
0.04
|
-
|
-
|
0.00
|
|
| Return on Capital Avg |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available